Prevention of PKG1a oxidation augments cardioprotection in the stressed heart

Journal of Clinical Investigation

Volumn 125, Issue 6, 2015, Pages 2468-2472

  Nakamura, Taishi ^a   Ranek, Mark J ^a   Lee, Dong I ^a   Hahn, Virginia Shalkey ^a   Kim, Choel ^b,c   Eaton, Philip ^d   Kass, David A ^a  

^a DEPARTMENT OF PATHOLOGY   (United States)

^b Department of Pharmacology ^*  (United States)

^c BAYLOR COLLEGE OF MEDICINE   (United States)

^d KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIC GMP DEPENDENT PROTEIN KINASE 1; GLUTATHIONE; MALONALDEHYDE; RGS PROTEIN; TRANSIENT RECEPTOR POTENTIAL CHANNEL 6; PRKG1 PROTEIN, MOUSE; TRANSIENT RECEPTOR POTENTIAL CHANNEL C; TRPC6 PROTEIN, MOUSE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CARDIAC PATIENT; CELL MEMBRANE; COMPARATIVE STUDY; CYTOSOL; DIMERIZATION; GENE EXPRESSION; HEART HYPERTROPHY; HEART MUSCLE CELL; HEART PROTECTION; HEART STRESS; HUMAN; IMMUNOBLOTTING; INTRACELLULAR TRANSPORT; LIPID PEROXIDATION; MECHANICAL STIMULATION; MECHANICAL STRESS; MOUSE; NONHUMAN; OXIDATION; OXIDATION REDUCTION STATE; OXIDATIVE STRESS; PRIORITY JOURNAL; RECEPTOR POTENTIAL; RESISTANCE BLOOD VESSEL; SIGNAL TRANSDUCTION; TRANSGENE; ANIMAL; CARDIOMEGALY; DISEASE MODEL; ENZYMOLOGY; GENETICS; METABOLISM; OXIDATION REDUCTION REACTION; PATHOLOGY; PROTEIN TRANSPORT; TRANSGENIC MOUSE;

ANIMALS; CARDIOMEGALY; CYCLIC GMP-DEPENDENT PROTEIN KINASE TYPE I; DISEASE MODELS, ANIMAL; HUMANS; MICE; MICE, TRANSGENIC; MYOCYTES, CARDIAC; OXIDATION-REDUCTION; OXIDATIVE STRESS; PROTEIN TRANSPORT; TRPC CATION CHANNELS;

EID: 84930389837     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI80275     Document Type: Article

References (27)

1. Francis SH, Busch JL, Corbin JD, Sibley D. cGMP-dependent protein kinases and cGMP phosphodiesterases in nitric oxide and cGMP action. Pharmacol Rev. 2010;62(3): 525-563.
2. Frantz S, et al. Stress-dependent dilated cardiomyopathy in mice with cardiomyocyte-restricted inactivation of cyclic GMP-dependent protein kinase I. Eur Heart J. 2013;34(16): 1233-1244.
3. Takimoto E, et al. Chronic inhibition of cyclic GMP phosphodiesterase 5A prevents and reverses cardiac hypertrophy. Nat Med. 2005;11(2): 214-222.
4. Kukreja RC, Salloum FN, Das A. Cyclic guanosine monophosphate signaling and phosphodiesterase- 5 inhibitors in cardioprotection. J Am Coll Cardiol. 2012;59(22): 1921-1927.
5. McMurray JJ, et al. Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med. 2014;371(11): 993-1004.
6. Greene SJ, et al. The cGMP signaling pathway as a therapeutic target in heart failure with preserved ejection fraction. J Am Heart Assoc. 2013;2(6): E000536.
7. Carnicer R, Crabtree MJ, Sivakumaran V, Casadei B, Kass DA. Nitric oxide synthases in heart failure. Antioxid Redox Signal. 2013;18(9): 1078-1099.
8. Stasch JP, et al. Targeting the heme-oxidized nitric oxide receptor for selective vasodilatation of diseased blood vessels. J Clin Invest. 2006;116(9): 2552-2561.
9. Tsai EJ, et al. Pressure-overload-induced subcellular relocalization/oxidation of soluble guanylyl cyclase in the heart modulates enzyme stimulation. Circ Res. 2012;110(2): 295-303.
10. Alverdi V, et al. cGMP-binding prepares PKG for substrate binding by disclosing the C-terminal domain. J Mol Biol. 2008;375(5): 1380-1393.
11. Burgoyne JR, et al. Cysteine redox sensor in PKGIa enables oxidant-induced activation. Science. 2007;317(5843): 1393-1397.
12. Prysyazhna O, Rudyk O, Eaton P. Single atom substitution in mouse protein kinase G eliminates oxidant sensing to cause hypertension. Nat Med. 2012;18(2): 286-290.
13. Burgoyne JR, Prysyazhna O, Rudyk O, Eaton P. cGMP-dependent activation of protein kinase G precludes disulfide activation: Implications for blood pressure control. Hypertension. 2012;60(5): 1301-1308.
14. Takimoto E, et al. Regulator of G protein signaling 2 mediates cardiac compensation to pressure overload and antihypertrophic effects of PDE5 inhibition in mice. J Clin Invest. 2009;119(2): 408-420.
15. Tokudome T, et al. Regulator of G-protein signaling subtype 4 mediates antihypertrophic effect of locally secreted natriuretic peptides in the heart. Circulation. 2008;117(18): 2329-2339.
16. Kuwahara K, et al. TRPC6 fulfills a calcineurin signaling circuit during pathologic cardiac remodeling. J Clin Invest. 2006;116(12): 3114-3126.
17. Kinoshita H, et al. Inhibition of TRPC6 channel activity contributes to the antihypertrophic effects of natriuretic peptides-guanylyl cyclase-A signaling in the heart. Circ Res. 2010;106(12): 1849-1860.
18. Koitabashi N, et al. Cyclic GMP/PKG-dependent inhibition of TRPC6 channel activity and expression negatively regulates cardiomyocyte NFAT activation Novel mechanism of cardiac stress modulation by PDE5 inhibition. J Mol Cell Cardiol. 2010;48(4): 713-724.
19. Wall ME, et al. Mechanisms associated with cGMP binding and activation of cGMP-dependent protein kinase. Proc Natl Acad Sci U S A. 2003;100(5): 2380-2385.
20. Lee E, Hayes DB, Langsetmo K, Sundberg EJ, Tao TC. Interactions between the leucine-zipper motif of cGMP-dependent protein kinase and the C-terminal region of the targeting subunit of myosin light chain phosphatase. J Mol Biol. 2007;373(5): 1198-1212.
21. Blanton RM, et al. Protein kinase g ia inhibits pressure overload-induced cardiac remodeling and is required for the cardioprotective effect of sildenafil in vivo. J Am Heart Assoc. 2012;1(5): E003731.
22. Michael SK, et al. High blood pressure arising from a defect in vascular function. Proc Natl Acad Sci U S A. 2008;105(18): 6702-6707.
23. Tang KM, et al. Regulator of G-protein signaling- 2 mediates vascular smooth muscle relaxation and blood pressure. Nat Med. 2003;9(12): 1506-1512.
24. Seo K, et al. Hyperactive adverse mechanical stress responses in dystrophic heart are coupled to transient receptor potential canonical 6 and blocked by cGMP-protein kinase G modulation. Circ Res. 2014;114(5): 823-832.
25. Graham S, et al. Canonical transient receptor potential 6 (TRPC6), a redox-regulated cation channel. J Biol Chem. 2010;285(30): 23466-23476.
26. Hall G, et al. Phosphodiesterase 5 inhibition ameliorates angiontensin II-induced podocyte dysmotility via the protein kinase G-mediated downregulation of TRPC6 activity. Am J Physiol Renal Physiol. 2014;306(12): F1442-F1450.
27. Kim EY, Anderson M, Dryer SE. Sustained activation of N-methyl-d-Aspartate receptors in podoctyes leads to oxidative stress, mobilization of transient receptor potential canonical 6 channels, nuclear factor of activated T cells activation, and apoptotic cell death. Mol Pharmacol. 2012;82(4): 728-737.